ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 0989

Mycophenolate Mofetil Shows Differential Modulation of Skin Gene Expression Across Autoantibody Subgroups of Diffuse Cutaneous Systemic Sclerosis

Medha Kanitkar1, Kristina Clark2, Voon Ong3 and Christopher Denton4

Affiliations: 1University College London UK, London, United Kingdom, 2University College London, London, United Kingdom, 3UCL Medical School Royal Free Campus, London, United Kingdom, 4University College London, UK, London, United Kingdom

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: Autoantibody(ies), Disease-Modifying Antirheumatic Drugs (Dmards), Gene Expression, Scleroderma, Systemic sclerosis

Session Information

Date: Monday, November 9, 2026

Title: (0977-0994) Systemic Sclerosis & Related Disorders - Basic and Translational Science Poster B

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy in systemic sclerosis (SSc) and recent clinical trial datasets show that MMF improves skin and lung SSc outcomes (1). Studies have previously delineated gene signatures of SSc skin response by measuring longitudinal modified Rodnan Skin Score (mRSS) across intrinsic, fibroproliferative and inflammatory molecular subsets (2). We have further explored modulation of gene expression in a well-characterised cohort of diffuse cutaneous systemic sclerosis (dcSSc) according to hallmark antinuclear antibody subgroups.

Methods: The BIOPSY cohort includes 68 well characterised SSc patients (including limited, diffuse subsets and healthy controls (HC)) prospectively collected from a large tertiary centre.  Skin biopsies and clinical data including treatment and mRSS were obtained from 16 HC, 14 established dcSSc, 19 early dcSSc at baseline, 11 at 3 months and 17 at 12 months. Bulk RNA sequencing was used to perform analyses including genome-wide transcriptome profiling of whole skin samples. Statistical analyses were performed using Microsoft Excel and R studio.

The BIOPSY cohort was used to validate the 41 top differentially expressed genes (DEGs) described in previous analyses (2). Per-gene paired Welch and Wilcoxon tests evaluated Δ-expression (change in mRSS from baseline→3m, baseline→12m) stratified by MMF therapy, mRSS response (improver Δ-mRSS ≤−3), and SSc-specific autoantibody (ATA, ARA and non-ARA/ATA in the MMF-treated dcSSc cohort).

Results: From the 41 top DEGs described in previous analyses (2), 39 are detected and validated in BIOPSY (p value < 0.05 and FDR < 0.05) in early dcSSc baseline vs HC (figure 1).

In MMF-treated subjects, ACTA2 (p=0.007), FN1 (p=0.030), and OAS1 (p=0.043) are significantly attenuated by 12 months (figure 2). Autoantibody class strongly modified the MMF transcriptomic response. ARA-MMF subjects showed marked suppression of the Interferon-stimulated gene axis (CXCL9/CXCL10/OAS1/STAT1/IDO1, all p value < 0.05 ARA vs non-ARA/ATA) but paradoxical COL1A1/COL3A1/TGFβ-fibrotic signature increased, whereas non-ARA/ATA antibody subjects showed the inverse pattern. ATA-MMF subjects displayed coherent attenuation of both inflammatory and fibrotic axes (figure 3).

Conclusion: A previously described MMF response gene signature is robustly recapitulated in our prospective BIOPSY cohort. MMF preferentially attenuates myofibroblast/extracellular matrix regulation genes (ACTA2, FN1) over 12 months. Autoantibody class fundamentally modifies the MMF transcriptomic response in dcSSc skin, suggesting personalised treatment strategies should account for ARA vs non-ARA disease biology. Future aims include identifying a genetic signature predictive of response to MMF in improving skin score trajectory at baseline.

References:
1. White B et al. Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis. ACR Open Rheumatol. 2025;7(3):e70004

< !  2.  Hinchcliff M et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol. 2013;133(8):1979-89

Supporting image 1Figure 1: Heatmap of the top 39 differentially expressed genes validated in the BIOPSY cohort from previous analyses, showing highest significance for the early dcSSc subset.

Supporting image 2Figure 2: 3 most significantly downregulated genes: OAS1, FN1 and ACTA2 (p value <0.05) in the diffuse SSc cohort within BIOPSY that have been validated from previous analyses, shown in red at 12 months following MMF treatment.

Supporting image 3Figure 3: Antibody-stratified MMF response at baseline vs 12 months follow-up in diffuse SSc in the BIOPSY cohort.


Disclosures: M. Kanitkar: None; K. Clark: None; V. Ong: Boehringer Ingelheim, 12,; C. Denton: Argenx, 12,, Bayer, 12,, Boehringer Ingelheim, 12,, Bristol Myers Squibb, 12,, Cabaletta, 12,, Calluna, 12,, Certa, 12,, CSL Behring, 12,, GlaxoSmithKline, 12,, Jannsen, 12,, Lilly, 12,, Novartis, 12,, Quell, 12,, Roche, 12,.

To cite this abstract in AMA style:

Kanitkar M, Clark K, Ong V, Denton C. Mycophenolate Mofetil Shows Differential Modulation of Skin Gene Expression Across Autoantibody Subgroups of Diffuse Cutaneous Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/mycophenolate-mofetil-shows-differential-modulation-of-skin-gene-expression-across-autoantibody-subgroups-of-diffuse-cutaneous-systemic-sclerosis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mycophenolate-mofetil-shows-differential-modulation-of-skin-gene-expression-across-autoantibody-subgroups-of-diffuse-cutaneous-systemic-sclerosis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology